173 related articles for article (PubMed ID: 37740222)
61. Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Fan Z; Luo H; Zhou J; Wang F; Zhang W; Wang J; Li S; Lai Q; Xu Y; Wang G; Liang A; Xu J
Oncol Rep; 2020 Nov; 44(5):2152-2164. PubMed ID: 32901871
[TBL] [Abstract][Full Text] [Related]
62. MicroRNA expression and clinical outcome of small cell lung cancer.
Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
[TBL] [Abstract][Full Text] [Related]
63. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
Li X; Zhu W; Chen Z; Luo L; Huang J; Zhang F; Li M; Guo Y; Guo L
Anticancer Drugs; 2014 Nov; 25(10):1152-64. PubMed ID: 25054270
[TBL] [Abstract][Full Text] [Related]
64. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
Kaufmann SH; Kalemkerian GP; Jasti R; Mabry M
Biochem Pharmacol; 1995 Dec; 50(12):1987-93. PubMed ID: 8849324
[TBL] [Abstract][Full Text] [Related]
65. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2.
Alimbetov D; Davis T; Brook AJ; Cox LS; Faragher RG; Nurgozhin T; Zhumadilov Z; Kipling D
Biogerontology; 2016 Apr; 17(2):305-15. PubMed ID: 26400758
[TBL] [Abstract][Full Text] [Related]
66. Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2.
Gurgis F; Åkerfeldt MC; Heng B; Wong C; Adams S; Guillemin GJ; Johns TG; Chircop M; Munoz L
Cell Death Discov; 2015; 1():15028. PubMed ID: 27551460
[TBL] [Abstract][Full Text] [Related]
67. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
68. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
[TBL] [Abstract][Full Text] [Related]
69. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.
Kim JH; Chae M; Kim WK; Kim YJ; Kang HS; Kim HS; Yoon S
Br J Pharmacol; 2011 Feb; 162(3):773-84. PubMed ID: 20973777
[TBL] [Abstract][Full Text] [Related]
70. ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response.
Nikolos F; Thomas C; Bado I; Gustafsson JÅ
Mol Cancer Res; 2018 Feb; 16(2):233-242. PubMed ID: 29117942
[TBL] [Abstract][Full Text] [Related]
71. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
72. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
73. In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide.
Li T; Fang J; Chu J; Liu X; Li Y; Zhu Y; Li S; Xiu Z; Li Y; Jin N; Zhu G; Sun L; Li X
J Cancer Res Clin Oncol; 2022 May; 148(5):1073-1085. PubMed ID: 35038020
[TBL] [Abstract][Full Text] [Related]
74. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
Zangemeister-Wittke U; Schenker T; Luedke GH; Stahel RA
Br J Cancer; 1998 Oct; 78(8):1035-42. PubMed ID: 9792147
[TBL] [Abstract][Full Text] [Related]
75. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity.
Köpper F; Bierwirth C; Schön M; Kunze M; Elvers I; Kranz D; Saini P; Menon MB; Walter D; Sørensen CS; Gaestel M; Helleday T; Schön MP; Dobbelstein M
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16856-61. PubMed ID: 24082115
[TBL] [Abstract][Full Text] [Related]
76. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
77. Blockade of the LRP16-PKR-NF-κB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy.
Li X; Wu Z; An X; Mei Q; Bai M; Hanski L; Li X; Ahola T; Han W
Elife; 2017 Aug; 6():. PubMed ID: 28820388
[TBL] [Abstract][Full Text] [Related]
78. IL-1β-induced and p38
Kulawik A; Engesser R; Ehlting C; Raue A; Albrecht U; Hahn B; Lehmann WD; Gaestel M; Klingmüller U; Häussinger D; Timmer J; Bode JG
J Biol Chem; 2017 Apr; 292(15):6291-6302. PubMed ID: 28223354
[TBL] [Abstract][Full Text] [Related]
79. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
80. Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway.
Ding L; Wang H; Lang W; Xiao L
J Biol Chem; 2002 Sep; 277(38):35305-13. PubMed ID: 12121973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
